Scholars Central

EditorialPublished 2014

Why Single Pharmacogenomic Trials Should be Very Significant?

Authors: Clive E Bowman

Journal of Pharmacogenomics & Pharmacoproteomics

Volume 5 · Issue 3 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Recasting traditional frequentist thinking into Bayesian beliefs illustrates that requirements for 'strength of evidence' should drive the sizing of pharmacogenomic trials not hopeful hyperbolae. There is no 'free lunch' in pharmacogenomic investigations.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Pharmacogenomics & Pharmacoproteomics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacogenomics & Pharmacoproteomics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Clive E Bowman”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels